InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), has more major news today as they have filed a provisional patent for pain program. This is a huge step in protecting intellectual and commercial property related to their groundbreaking research into the potential of non-THC cannabinoids to treat pain using a topical formulation..
In response to compelling recent data, India Globalization Capital, Inc. (NYSE MKT: IGC) announced it has made a highly significant novel breakthrough in treating Alzheimer’s disease with tetrahydrocannabinol (THC)—an advancement that could potentially bring much-needed relief to Alzheimer’s sufferers.
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), has seen a strong upward trend over the past few weeks, going from a close of $.27 at the end of August to $.50 currently on the back of strong announcements, and people are taking notice.
Algae Dynamics Corp. (OTCQB: ADYNF), a company engaged in developing unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils, is making international news through its current collaboration with the University of Western Ontario (now rebranded as Western University).
PotNetwork Holding, Inc. (OTC: POTN) this morning announced that its Diamond CBD subsidiary has been selected as an exclusive premier sponsor of Tommy Chong’s Blazer’s Cup, a large cannabis festival set to take place beginning on December 2, 2017, in San Bernardino, California.
ChineseInvestors.com, Inc. (OTCQB: CIIX) announced in an 8K SEC filing that Paul Dickman has returned as its chief financial officer, effective September 25, 2017.
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that it has signed a Letter of Intent (“LOI”) to acquire a Denver, Colorado-based company that is approaching $1 million in annual revenue.
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids.
InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today an update to its investors and stakeholders on the significant advancements in its proprietary technology for the microbial biosynthesis of cannabinoids..
Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) welcomes Kanata Earth Inc. as the first participant in the recently announced Wheaton Licensing Program and the cornerstone of its First Nations strategy.
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), announces that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.
